Latest & greatest articles for cerebral palsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cerebral palsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cerebral palsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cerebral palsy

1. Cerebral palsy in adults

, despite having enteral anti-dystonic drug treatment or botulinum toxin type A [5] treatment. Provide information and discuss the procedure, including intrathecal baclofen testing, with the person (and their family or carer, if agreed) as described in recommendations 1.3.13 to 1.3.16. Deep br Deep brain stimulation ain stimulation 1.3.25 If adults with cerebral palsy continue to have severe and painful dystonia, despite having enteral anti-dystonic drug treatment or botulinum toxin type A treatment (...) , consider referring them to a specialised centre with experience in providing deep brain stimulation. See also NICE interventional procedures guidance on deep brain stimulation for tremor and dystonia (excluding Parkinson's diseas). Cerebral palsy in adults (NG119) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 19 of 64T o find out why the committee made the recommendations on neurosurgical treatments to reduce

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Cerebral palsy in under 25s: assessment and management

and developmental follow-up programme (see section 1.3) for children who have any of the risk factors listed in recommendation 1.1.1. Cerebral palsy in under 25s: assessment and management (NG62) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 6 of 461.2 Causes of cerebral palsy 1.2.1 When assessing the likely cause of cerebral palsy in a child, recognise that a number of MRI-identified brain abnormalities have been reported (...) of functional impairment than other causes. 1.2.5 Recognise that the clinical syndrome of neonatal encephalopathy can result from various pathological events, such as a hypoxic–ischaemic brain injury or sepsis, and if there has been more than 1 such event they may interact to damage the developing brain. 1.2.6 When assessing the likely cause of cerebral palsy, recognise that neonatal encephalopathy has been reported at the following approximate prevalences in Cerebral palsy in under 25s: assessment

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

3. Cerebral palsy

Cerebral palsy Cerebral palsy - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Cerebral palsy Last reviewed: February 2019 Last updated: February 2019 Summary An umbrella term referring to a non-progressive disease of the brain originating during the antenatal, neonatal, or early postnatal period when brain neuronal connections are still evolving. Most common cause of childhood disability affecting 2.5 per 1000 (...) , and extremity deformity. Definition Cerebral palsy (CP) is an umbrella term referring to a non-progressive disease of the brain originating during the antenatal, neonatal, or early postnatal period when brain neuronal connections are still evolving. Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007 Feb;109:8-14. http://www.ncbi.nlm.nih.gov/pubmed/17370477?tool=bestpractice.com Secondary effects of spasticity

2019 BMJ Best Practice

4. Sialanar (glycopyrronium) - for treating severe drooling of saliva in children and adolescents (aged 3 years and above) with conditions affecting the nervous system, such as cerebral palsy, epilepsy and neurodegenerative diseases

Sialanar (glycopyrronium) - for treating severe drooling of saliva in children and adolescents (aged 3 years and above) with conditions affecting the nervous system, such as cerebral palsy, epilepsy and neurodegenerative diseases 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 21 July 2016 EMA/555265/2016 Committee (...) Pharmacopoeia or blood pressure bpm beats per minute CE Conformité Européene CEP Certificate of Suitability of the Ph.Eur. CHMP Committee for Medicinal Products for Human Use CHO chinese hamster ovary C max maximum concentration in plasma (or serum) CI confidence interval Cl (total plasma) clearance CMS Concerned Member State CNS central nervous system CoA Certificate of Analysis CP cerebral palsy CRS Chemical Reference Substance (official standard) CSF cerebrospinal fluid CSR clinical study report %CV

2016 European Medicines Agency - EPARs

5. Cerebral Palsy

Cerebral Palsy Cerebral Palsy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Cerebral Palsy Cerebral Palsy Aka: Cerebral Palsy From (...) Palsy Brain cancer Routine Left lateral position more comfortable for pelvic Educate about injury risks risk s XI. References Majoewsky (2012) EM:Rap 2(9): 4 Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Cerebral Palsy." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Cerebral Palsy (C0007789) Definition (CHV) birth injury of the brain nerve

2018 FP Notebook

6. Cerebral palsy

, diplegias, cerebral palsies , Little disease, Little's disease Files Rapid Response Reference List Published : January 18, 2017 Follow us: © 2017 Canadian Agency for Drugs and Technologies in Health Get our newsletter: 2017 9. Intrathecal baclofen for treating spasticity in children with cerebral palsy . BACKGROUND: Cerebral palsy is a disorder of movement and posture arising from a non-progressive lesion in the developing brain. Spasticity, a disorder of increased muscle tone, is the most common motor (...) 2018 Summary An umbrella term referring to a non-progressive disease of the brain originating during the antenatal, neonatal, or early postnatal period when brain neuronal connections are still evolving. Most common cause of childhood disability affecting 2.5 per 1000 individuals (...) deformity. Definition Cerebral palsy (CP) is an umbrella term referring to a non-progressive disease of the brain originating during the antenatal, neonatal, or early postnatal period when brain neuronal connections

2018 Trip Latest and Greatest

7. Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy. Full Text available with Trip Pro

Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy. Cerebral palsy (CP) is the most common cause of physical disabilities in children in high-income countries. Spasticity is the most common motor disturbance in CP. Botulinum toxin type A (BoNT-A) is considered the first-line treatment for focal spasticity in people with CP.To evaluate the effectiveness and safety of BoNT-A compared to other treatments used in the management of lower limb spasticity

2019 Cochrane

8. Early Diagnosis for Children with Cerebral Palsy: Clinical Effectiveness and Guidelines

Early Diagnosis for Children with Cerebral Palsy: Clinical Effectiveness and Guidelines Early Diagnosis for Children with Cerebral Palsy: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Early Diagnosis for Children with Cerebral Palsy: Clinical Effectiveness and Guidelines Early Diagnosis for Children with Cerebral Palsy: Clinical Effectiveness and Guidelines Published on: January 10, 2018 Project Number: RB1181-000 Product Line: Research Type: Other Diagnostics (...) Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of early diagnosis in children with cerebral palsy? What are the evidence-based guidelines addressing early diagnosis in children with cerebral palsy? Key Message Five systematic reviews, one with meta-analysis, one randomized controlled trial, and one non-randomized study were identified regarding the clinical effectiveness of early diagnosis in children with cerebral palsy. Tags diagnostic tests

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews. Full Text available with Trip Pro

Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews. Cerebral palsy is an umbrella term that encompasses disorders of movement and posture attributed to non-progressive disturbances occurring in the developing foetal or infant brain. As there are diverse risk factors and aetiologies, no one strategy will prevent cerebral palsy. Therefore, there is a need to systematically consider all potentially relevant interventions for prevention.PrimaryTo (...) summarise the evidence from Cochrane Systematic Reviews regarding effects of neonatal interventions for preventing cerebral palsy (reducing cerebral palsy risk).SecondaryTo summarise the evidence from Cochrane Systematic Reviews regarding effects of neonatal interventions that may increase cerebral palsy risk.We searched the Cochrane Database of Systematic Reviews (27 November 2016) for reviews of neonatal interventions reporting on cerebral palsy. Two review authors assessed reviews for inclusion

2018 Cochrane

10. Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy

Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review) | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share January 26, 2010 ; 74 (4) Special Article Practice Parameter: Pharmacologic treatment of spasticity (...) in children and adolescents with cerebral palsy (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society M. R. Delgado , D. Hirtz , M. Aisen , S. Ashwal , D. L. Fehlings , J. McLaughlin , L. A. Morrison , M. W. Shrader , A. Tilton , J. Vargus-Adams First published January 25, 2010, DOI: https://doi.org/10.1212/WNL.0b013e3181cbcd2f M. R. Delgado D. Hirtz M. Aisen S. Ashwal D. L. Fehlings J

2010 American Academy of Neurology

11. Factors in the Efficacy, Safety, and Impact on Quality of Life for Treatment of Drooling with Botulinum Toxin Type A in Patients with Cerebral Palsy. (Abstract)

Factors in the Efficacy, Safety, and Impact on Quality of Life for Treatment of Drooling with Botulinum Toxin Type A in Patients with Cerebral Palsy. To assess the efficacy and safety of botulinum toxin A (BoNT-A) injected in both submandibular and parotid versus only in parotid glands as a treatment for drooling in patients with spastic and dyskinetic cerebral palsy (CP), including an assessment of impact on quality of life (QoL) based on items from the International Classification

2017 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

12. Interventions for Children with Cerebral Palsy: Guidelines

Interventions for Children with Cerebral Palsy: Guidelines Interventions for Children with Cerebral Palsy: Guidelines | CADTH.ca Find the information you need Interventions for Children with Cerebral Palsy: Guidelines Interventions for Children with Cerebral Palsy: Guidelines Published on: January 18, 2017 Project Number: RA0884-000 Product Line: Research Type: Other Diagnostics Report Type: Reference List Result type: Report Question What are the evidence-based guidelines regarding (...) interventions for children with cerebral palsy? Key Message No evidence-based guidelines were identified regarding interventions for children with cerebral palsy. Tags nervous system, pediatrics, cerebral palsy, spastic, diplegia, diplegias, cerebral palsies, Little disease, Little's disease Files Rapid Response Reference List Published : January 18, 2017 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth

asa neuroprotective agent is unknown, it hasa number of biologically plausible actions which may contribute to a protective effect on the preterm neonatal brain. The most common pathological lesion associated with cerebral palsy in preterm infants is periventri- cular white matter injury. 5 Oligodendrocytes constitutea major glial population in the white matter. N-methyl-D-aspartic acid (NMDA) receptors on oligodendrocytes are thought to be important in the glial injury process. NMDA receptor (...) Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Scientific Impact Paper No. 29 August 2011Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth 1. Background The prevalence of preterm birth is increasing. 1 While the survival of infants born preterm has improved, 2 the prevalence of cerebral palsy has risen. 3 The incidence of cerebral palsy decreases significantly with increasing

2011 Royal College of Obstetricians and Gynaecologists

14. Single Event Multi-Level Surgeries for Children, Adolescents, and Young Adults with Cerebral Palsy or Other Similar Neuromotor Conditions

, Definitions for terms marked with *, and How to Cite this Guideline may be found in the Appendices. INTRODUCTION / BACKGROUND Cerebral Palsy (CP) is a disorder of movement and posture caused by a static, non-progressive, neurological incident, occurring in the fetal or infant brain. As a result, individuals often have secondary impairments including musculoskeletal pathologies consisting of abnormal muscle tone, loss of selective motor control, impaired balance, impaired posture, and impaired mobility (...) Single Event Multi-Level Surgeries for Children, Adolescents, and Young Adults with Cerebral Palsy or Other Similar Neuromotor Conditions Evidence-Based Clinical Care Guideline for Physical Therapy Management of Single Event Multi-Level Surgeries for Children, Adolescents, and Young Adults with Cerebral Palsy or Other Similar Neuromotor Conditions Guideline (48) Copyright © 2018 Cincinnati Children's Hospital Medical Center; all rights reserved. Page 1 of 33 February 6, 2019 Abbreviations

2019 Cincinnati Children's Hospital Medical Center

15. Periodontal disease in children and young adults with cerebral palsy: a systematic review

Periodontal disease in children and young adults with cerebral palsy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2019 PROSPERO

16. Cerebral palsy

Cerebral palsy Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

17. Intrathecal baclofen for treating spasticity in children with cerebral palsy. (Abstract)

Intrathecal baclofen for treating spasticity in children with cerebral palsy. Cerebral palsy is a disorder of movement and posture arising from a non-progressive lesion in the developing brain. Spasticity, a disorder of increased muscle tone, is the most common motor difficulty and is associated with activity limitation to varying degrees in mobility and self care.Oral baclofen, a gamma-aminobutyric acid (GABA) agonist, has been used in oral form to treat spasticity for some time, but it has (...) baclofen pumps over six months.The four short-term studies demonstrated that intrathecal baclofen therapy reduces spasticity in children with cerebral palsy. However, two of these studies utilised inappropriate techniques for statistical analysis of results. The single longer-term study demonstrated minimal reduction in spasticity with the use of intrathecal baclofen therapy.One of the short-term studies and the longer term study showed improvement in comfort and ease of care. The longer term study

2015 Cochrane

18. Combining constraint-induced movement therapy and action-observation training in children with unilateral cerebral palsy: a randomized controlled trial. Full Text available with Trip Pro

Combining constraint-induced movement therapy and action-observation training in children with unilateral cerebral palsy: a randomized controlled trial. Upper limb (UL) deficits in children with unilateral cerebral palsy (uCP) have traditionally been targeted with motor execution treatment models, such as modified Constraint-Induced Movement Therapy (mCIMT). However, new approaches based on a neurophysiological model such as Action-Observation Training (AOT) may provide new opportunities (...) human motion. The primary outcome measure will be the Assisting Hand Assessment. Secondary outcomes comprise clinical assessments across body function, activity and participation level of the International Classification of Function, Disability and Health. Furthermore, to quantitatively evaluate UL movement patterns, a three-dimensional motion analysis will be conducted. UL function will be assessed at baseline, immediately before and after intervention and at 6 months follow up. Brain imaging

2018 BMC Pediatrics Controlled trial quality: predicted high

19. Effectiveness of aquatic interventions for children with cerebral palsy: systematic review of the current literature

Effectiveness of aquatic interventions for children with cerebral palsy: systematic review of the current literature Effectiveness of aquatic interventions for children with cerebral palsy: systematic review of the current literature Effectiveness of aquatic interventions for children with cerebral palsy: systematic review of the current literature Blohm D CRD summary The review concluded that the evidence suggested aquatic interventions were beneficial for children and adolescents (...) with cerebral palsy. The author's conclusions reflected the evidence presented, but the potential for missed studies, lack of reporting of review methods, and limitations in the evidence mean the reliability of the conclusions is uncertain. Authors' objectives To evaluate the effectiveness of aquatic interventions for children or adolescents with cerebral palsy. Searching PubMed, CINAHL, PEDro, SPORTDiscus and The Cochrane Library were searched for articles in English or German published in peer-reviewed

2011 DARE.

20. Impact of Hippotherapy on Gross Motor Function and Quality of Life in Children with Bilateral Cerebral Palsy: A Randomized Open-Label Crossover Study. (Abstract)

Impact of Hippotherapy on Gross Motor Function and Quality of Life in Children with Bilateral Cerebral Palsy: A Randomized Open-Label Crossover Study. This study investigated the effect of hippotherapy on gross motor function (Gross Motor Function Measure [GMFM]-66, GMFM dimension E and D) and quality of life (Child Health Questionnaire [CHQ 28], KIDSCREEN-27 parental versions) in children with bilateral spastic cerebral palsy. Seventy-three children (age: 9.1 ± 3.3 years; male = 44; GMFCS (...) psychosocial quality of life scores than children who completed the whole study (CHQ-28 "psychosocial dimension"; KIDSCREEN-27 "mood and emotional dimension"). Our data are in line with previous reports and suggest that hippotherapy shows distinct therapeutic strengths with regard to promoting upright stand and gait in children with cerebral palsy. Children with higher psychosocial burden of disease may need special support to get access to and benefit from intensified physiotherapy programs.Georg Thieme

2018 Neuropediatrics Controlled trial quality: uncertain